Switch theme
Sign up to access all valuation multiples
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
2009
109
Last FY Revenue n/a
LTM EBITDA -$195M
$109M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kodiak Sciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$195M.
In the most recent fiscal year, Kodiak Sciences achieved revenue of n/a and an EBITDA of -$150M.
Kodiak Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kodiak Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$195M | XXX | -$150M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$205M | XXX | -$187M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$196M | XXX | -$176M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kodiak Sciences's stock price is $3.
Kodiak Sciences has current market cap of $180M, and EV of $109M.
See Kodiak Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $109M | $180M | XXX | XXX | XXX | XXX | $-3.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kodiak Sciences has market cap of $180M and EV of $109M.
Kodiak Sciences's trades at n/a EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Kodiak Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kodiak Sciences has a P/E ratio of -0.9x.
See valuation multiples for Kodiak Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $180M | XXX | $180M | XXX | XXX | XXX |
| EV (current) | $109M | XXX | $109M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.5x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKodiak Sciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Kodiak Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kodiak Sciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kodiak Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kodiak Sciences acquired XXX companies to date.
Last acquisition by Kodiak Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Kodiak Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kodiak Sciences founded? | Kodiak Sciences was founded in 2009. |
| Where is Kodiak Sciences headquartered? | Kodiak Sciences is headquartered in United States of America. |
| How many employees does Kodiak Sciences have? | As of today, Kodiak Sciences has 109 employees. |
| Who is the CEO of Kodiak Sciences? | Kodiak Sciences's CEO is Dr. Victor Perlroth, M.D.. |
| Is Kodiak Sciences publicy listed? | Yes, Kodiak Sciences is a public company listed on NAS. |
| What is the stock symbol of Kodiak Sciences? | Kodiak Sciences trades under KOD ticker. |
| When did Kodiak Sciences go public? | Kodiak Sciences went public in 2018. |
| Who are competitors of Kodiak Sciences? | Similar companies to Kodiak Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kodiak Sciences? | Kodiak Sciences's current market cap is $180M |
| Is Kodiak Sciences profitable? | Yes, Kodiak Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kodiak Sciences? | Kodiak Sciences's last 12 months EBITDA is -$195M. |
| What is the current EV/EBITDA multiple of Kodiak Sciences? | Current EBITDA multiple of Kodiak Sciences is -0.6x. |
| What is the current FCF of Kodiak Sciences? | Kodiak Sciences's last 12 months FCF is -$92.6M. |
| What is the current EV/FCF multiple of Kodiak Sciences? | Current FCF multiple of Kodiak Sciences is -1.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
